Hovione, a global group dedicated to the cGMP development and manufacture of APIs, and Solvia, a privately held solutions provider based in Basel, Switzerland, have established a collaboration focused on the development and GMP supply of pharmaceutical co-crystals.

The partnership provides Hovione access to Solvias’ co-crystallization expertise and capabilities, thus reinforcing and complementing the crystal design solutions to overcome poor bioavailability and other drug delivery challenges. Solvias continues its strategy of partnering to enhance access to its solid-state solutions.

The collaboration strengthens Hovione’s expertise and experience in overcoming drug delivery challenges and also the supply of GMP materials from phase I to commercial scale, with Solvias’ excellence in solid state chemistry. Hovione offers a series of particle engineering technologies focused on amorphous solid dispersions, crystal design and reduction and control of particle size.

“We are delighted to announce this collaboration with Solvias increasing the breadth of drug delivery solutions through our particle design offering,” said Dr. Colin Minchom, vice president of particle design, Hovione. “Solvias has a tremendous reputation for science, quality and expertise in crystal design for improved drug performance. This agreement reinforces our strategy of combining strengths with innovative companies to allow our customers a seamless and integrated approach to their drug delivery challenges.”